Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

被引：37

作者：

Mina, Lida A. ^{[1
]}

Lim, Shannon ^{[2
]}

Bahadur, Shakeela W. ^{[1
]}

Firoz, Abdul T. ^{[3
]}

机构：

[1] Banner MD Anderson Canc Ctr, Hematol Oncol Dept, Gilbert, AZ 85234 USA

[2] Banner MD Anderson Canc Ctr, Pharm Dept, Gilbert, AZ 85234 USA

[3] Arizona State Univ, Sci Dept, Tempe, AZ USA

来源：

BREAST CANCER-TARGETS AND THERAPY | 2019年 / 11卷

关键词：

breast cancer; immunotherapy; PD1; PDL1; atezolizumab; COMBINED NIVOLUMAB; ESTROGEN-RECEPTOR; ADVANCED MELANOMA; OPEN-LABEL; PEMBROLIZUMAB; IPILIMUMAB; CHEMOTHERAPY; DOCETAXEL; PATTERNS; SURVIVAL;

D O I：

10.2147/BCTT.S184710

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the most common type of cancer affecting women in the United States. Triple-negative breast cancer remains the most aggressive molecular subtype secondary to a lack of therapeutic targets. The search for a target has led us to investigate immunotherapeutic agents. Immunotherapy has recently demonstrated significant breakthroughs in various types of cancers that are refractory to traditional therapies including melanoma and Non-Small Cell Lung Cancer (NSCLC). Breast cancer however remains one of the tumors that was initially least investigated because of being considered to have a low immunogenic potential and a low mutational load. Over the past few years, antiPD1/PDL1 drugs have started to make progress in the triple-negative subtype with more promising outcomes. In this report, we review the treatment of triple-negative breast cancer and specifically shed light on advances in immunotherapy and newly approved drugs in this challenging disease.

引用

页码：321 / 328

页数：8

共 65 条

[1]

Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]

[2] Current Landscape of Immunotherapy in Breast Cancer: A Review [J].

Adams, Sylvia ;

Gatti-Mays, Margaret E. ;

Kalinsky, Kevin ;

Korde, Larissa A. ;

Sharon, Elad ;

Amiri-Kordestani, Laleh ;

Bear, Harry ;

McArthur, Heather L. ;

Frank, Elizabeth ;

Perlmutter, Jane ;

Page, David B. ;

Vincent, Benjamin ;

Hayes, Jennifer F. ;

Gulley, James L. ;

Litton, Jennifer K. ;

Hortobagyi, Gabriel N. ;

Chia, Stephen ;

Krop, Ian ;

White, Julia ;

Sparano, Joseph ;

Disis, Mary L. ;

Mittendorf, Elizabeth A. .

JAMA ONCOLOGY, 2019, 5 (08) :1205-1214

[3] Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. [J].

Adams, Sylvia ;

Loi, Sherene ;

Toppmeyer, Deborah ;

Cescon, David W. ;

De laurentiis, Michele ;

Nanda, Rita ;

Winer, Eric P. ;

Mukai, Hirofumi ;

Tamura, Kenji ;

Armstrong, Anne ;

Liu, Minetta C. ;

Iwata, Hiroji ;

Ryvo, Larisa ;

Wimberger, Pauline ;

Card, Deborah ;

Ding, Yu ;

Karantza, Vassiliki ;

Schmid, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[4]

Allred C, 2009, J NATL COMPR CANC NE, V7, pS1

[5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[6] Inflammation and cancer: back to Virchow? [J].

Balkwill, F ;

Mantovani, A .

LANCET, 2001, 357 (9255) :539-545

[7] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].

Bauer, Katrina R. ;

Brown, Monica ;

Cress, Rosemary D. ;

Parise, Carol A. ;

Caggiano, Vincent .

CANCER, 2007, 109 (09) :1721-1728

[8] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[9] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[10] Nivolumab: targeting PD-1 to bolster antitumor immunity [J].

Brahmer, Julie R. ;

Hammers, Hans ;

Lipson, Evan J. .

FUTURE ONCOLOGY, 2015, 11 (09) :1307-1326

← 1 2 3 4 5 6 7 →